PMID- 31574846 OWN - NLM STAT- MEDLINE DCOM- 20191014 LR - 20221005 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 98 IP - 39 DP - 2019 Sep TI - Mechanisms of action of molecules with anti-TNF-alpha activity on intestinal barrier inflammation: A systematic review protocol. PG - e17285 LID - 10.1097/MD.0000000000017285 [doi] LID - e17285 AB - BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha), among cytokines that mediate the inflammatory process, plays an important role in diseases involving the loss of intestinal barrier integrity. Several molecules with anti-TNF-alpha activity have been studied aiming to develop new therapies. The purpose of this paper is to describe the systematic review protocol of experimental studies that determine mechanisms of action of molecules with anti-TNF-alpha activity on intestinal barrier inflammation. METHODS: This protocol is guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyzes Protocols (PRISMA-P). The databases to be searched are PubMed, EMBASE, Scopus, ScienceDirect, and Web of Science. Experimental studies in rats or mice that assessed the activity of anti-TNF-alpha molecules in models of intestinal barrier inflammation will be included in the systematic review. Studies characteristics, experimental model, and main results will be described and the bias risk assessment will be performed. Two independent reviewers will perform study selection, data extraction, and methodological quality assessment. A narrative synthesis will be made for the included studies. Also, if sufficient data is available, a meta-analysis will be conducted. I statistics will be used to assess heterogeneity. RESULTS: The present protocol will assist in producing a systematic review that identifies the mechanisms underlying the reduction of TNF-alpha in intestinal barrier inflammation models. CONCLUSION: The systematic review may contribute to the theoretical basis of research on new molecules with anti-TNF-alpha potential and, consequently, in the development of new therapies employed in humans. PROSPERO REGISTRATION NUMBER: CRD42019131862. FAU - Lima, Mayara Santa Rosa AU - Lima MSR AD - Biochemistry Postgraduate Program, Biosciences Center. FAU - Lima, Vanessa Cristina Oliveira de AU - Lima VCO AD - Biochemistry Postgraduate Program, Biosciences Center. FAU - Piuvezam, Grasiela AU - Piuvezam G AD - Collective Health Postgraduate Program (PPGSCoL). FAU - Azevedo, Kesley Pablo Morais de AU - Azevedo KPM AD - Collective Health Postgraduate Program (PPGSCoL). FAU - Maciel, Bruna Leal Lima AU - Maciel BLL AD - Nutrition Postgraduate Program, Center for Health Sciences, Federal University of Rio Grande do Norte, Natal, RN, Brazil. FAU - Morais, Ana Heloneida de Araujo AU - Morais AHA AD - Biochemistry Postgraduate Program, Biosciences Center. AD - Nutrition Postgraduate Program, Center for Health Sciences, Federal University of Rio Grande do Norte, Natal, RN, Brazil. LA - eng PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (Gastrointestinal Agents) RN - 0 (Tumor Necrosis Factor-alpha) SB - IM MH - Animals MH - Gastrointestinal Agents/*pharmacology MH - Humans MH - Inflammation MH - Intestinal Mucosa/*drug effects MH - Research Design MH - Systematic Reviews as Topic MH - Tumor Necrosis Factor-alpha/antagonists & inhibitors/*drug effects PMC - PMC6775351 COIS- The authors have no conflicts of interest to disclose. EDAT- 2019/10/03 06:00 MHDA- 2019/10/15 06:00 PMCR- 2019/09/27 CRDT- 2019/10/03 06:00 PHST- 2019/10/03 06:00 [entrez] PHST- 2019/10/03 06:00 [pubmed] PHST- 2019/10/15 06:00 [medline] PHST- 2019/09/27 00:00 [pmc-release] AID - 00005792-201909270-00055 [pii] AID - MD-D-19-06745 [pii] AID - 10.1097/MD.0000000000017285 [doi] PST - ppublish SO - Medicine (Baltimore). 2019 Sep;98(39):e17285. doi: 10.1097/MD.0000000000017285.